Nimvastid
Cholinesterase Inhibitor for Alzheimer's and Parkinson's Disease Dementia
Quick Facts About Nimvastid
Key Takeaways About Nimvastid
- Dual enzyme inhibition: Nimvastid blocks both acetylcholinesterase and butyrylcholinesterase, increasing brain acetylcholine levels to improve cognitive symptoms of dementia
- Gradual dose increase required: Treatment starts at 1.5 mg twice daily and must be slowly increased over weeks to minimise gastrointestinal side effects
- Always take with food: Taking Nimvastid capsules with meals significantly reduces nausea and vomiting
- Do not stop for more than 3 days: If treatment is interrupted for more than 3 days, you must consult your doctor before resuming, as re-titration from the lowest dose may be necessary
- Common side effects are gastrointestinal: Nausea, vomiting, diarrhoea, and decreased appetite are the most frequent side effects, especially during dose escalation
What Is Nimvastid and What Is It Used For?
Nimvastid is a cholinesterase inhibitor containing rivastigmine, prescribed for the treatment of mild to moderately severe Alzheimer's dementia and dementia associated with Parkinson's disease. It works by blocking enzymes that break down acetylcholine in the brain, thereby improving cognitive function, memory, and the ability to perform daily activities.
Nimvastid belongs to a class of medications known as cholinesterase inhibitors. The active substance, rivastigmine, has a unique dual mechanism of action: it inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), two enzymes responsible for breaking down the neurotransmitter acetylcholine in the brain. In patients with Alzheimer's disease and Parkinson's disease dementia, certain nerve cells in the brain progressively degenerate and die, leading to significantly reduced levels of acetylcholine – a chemical messenger essential for communication between nerve cells, particularly those involved in memory, learning, and attention.
By blocking both of these enzymes, Nimvastid helps to maintain higher concentrations of acetylcholine in the brain, partially compensating for the loss of functioning nerve cells. This mechanism of action distinguishes rivastigmine from some other cholinesterase inhibitors (such as donepezil) that primarily inhibit only AChE. The dual inhibition is thought to be particularly beneficial because BuChE activity increases as Alzheimer's disease progresses, potentially making rivastigmine more effective in later stages of the disease.
Nimvastid is approved for the treatment of two main conditions. In Alzheimer's disease, it is used for adults with mild to moderately severe dementia, which represents the early to middle stages of the disease. According to the European Medicines Agency (EMA), rivastigmine has demonstrated statistically significant improvements in cognitive function, global functioning, and activities of daily living compared to placebo in multiple randomised controlled trials.
For Parkinson's disease dementia (PDD), Nimvastid capsules are also approved. Dementia affects approximately 75–80% of patients with Parkinson's disease during the course of their illness. Rivastigmine is one of the few medications that has shown clinical benefit in this specific type of dementia, as demonstrated in the landmark EXPRESS study, a large randomised controlled trial published in the New England Journal of Medicine.
Nimvastid is a generic version of the original rivastigmine product (Exelon), manufactured by KRKA. It contains exactly the same active substance in the same amounts and has been demonstrated to be bioequivalent to the originator product. Rivastigmine has been used worldwide since 1997 and is included in the World Health Organization's Model List of Essential Medicines for treating Alzheimer's disease.
What Should You Know Before Taking Nimvastid?
Before starting Nimvastid, inform your doctor about all medical conditions, especially heart disease, stomach ulcers, seizures, asthma, and liver or kidney problems. Nimvastid is contraindicated in patients allergic to rivastigmine or carbamate derivatives. Special precautions are needed for patients with low body weight or a history of gastrointestinal disorders.
Contraindications
You should not take Nimvastid if any of the following apply to you:
- Allergy to rivastigmine or to any of the other ingredients in Nimvastid (listed in the composition section below)
- Allergy to carbamate derivatives – rivastigmine belongs to the carbamate class, and cross-reactivity is possible
- Previous severe skin reaction to rivastigmine transdermal patches – if you experienced blistering, increasing skin inflammation, or swelling that spread beyond the patch site and did not improve within 48 hours after patch removal, you should not use any form of rivastigmine, including capsules
Warnings and Precautions
Talk to your doctor before taking Nimvastid if you have or have ever had any of the following conditions:
- Heart disease – including irregular or slow heartbeat (bradycardia), QTc prolongation, family history of QTc prolongation, torsades de pointes, or low blood levels of potassium or magnesium. Cholinesterase inhibitors can potentially worsen conduction disorders and cause bradycardia
- Active stomach or duodenal ulcer – rivastigmine increases gastric acid secretion through its cholinergic mechanism of action, which may exacerbate peptic ulcer disease
- Urinary obstruction or difficulty urinating – cholinergic stimulation can affect bladder function
- Seizures (epilepsy) – cholinergic drugs may potentially lower the seizure threshold
- Asthma or severe respiratory disease – cholinergic effects may increase bronchoconstriction and airway secretions
- Kidney impairment – although rivastigmine is primarily metabolised at the site of action, dose adjustment may be needed in severe renal impairment
- Liver impairment – rivastigmine exposure may be increased in patients with hepatic dysfunction
- Tremor – cholinergic drugs may worsen or induce tremor
- Low body weight (especially less than 50 kg) – patients with low body weight have a higher incidence of adverse reactions, particularly gastrointestinal effects. Careful dose titration and monitoring is essential
Gastrointestinal side effects such as nausea, vomiting, and diarrhoea are common, particularly during dose escalation. Prolonged vomiting or diarrhoea can lead to dehydration, which can be serious, especially in elderly patients. If you experience persistent gastrointestinal symptoms, contact your doctor promptly, as dose reduction or temporary discontinuation may be necessary.
If you have not taken Nimvastid for more than 3 consecutive days, do not take the next dose until you have spoken with your doctor. Restarting at the previous dose after a treatment gap can cause severe gastrointestinal side effects. Your doctor will likely advise you to restart at the lowest dose (1.5 mg twice daily) and gradually re-titrate upward.
Use in Children and Adolescents
There is no relevant use of Nimvastid in children and adolescents. Alzheimer's disease and Parkinson's disease dementia do not occur in the paediatric population. Nimvastid should not be used in patients under 18 years of age.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. The benefit of using Nimvastid during pregnancy must be weighed against possible effects on the unborn child. Nimvastid should not be used during pregnancy unless clearly necessary and only under close medical supervision.
You should not breastfeed while taking Nimvastid, as rivastigmine may pass into breast milk and could affect the nursing infant.
Driving and Operating Machinery
Your doctor will advise you whether your condition allows you to drive safely and operate machinery. Nimvastid can cause dizziness and drowsiness, particularly when starting treatment or when the dose is increased. If you experience these effects, do not drive, operate machinery, or perform any activities that require full alertness. Additionally, Alzheimer's disease and Parkinson's disease themselves may impair the ability to drive or operate machinery safely.
How Does Nimvastid Interact with Other Drugs?
Nimvastid should not be combined with other cholinesterase inhibitors or metoclopramide. It can interact with anticholinergic medications, beta-blockers, succinylcholine-type muscle relaxants during anaesthesia, and drugs that prolong the QT interval. Always inform your doctor and pharmacist about all medications you are currently taking.
Drug interactions are an important consideration for patients taking Nimvastid, as many people with Alzheimer's disease or Parkinson's disease dementia take multiple medications simultaneously. The pharmacokinetic profile of rivastigmine makes it somewhat less prone to cytochrome P450-mediated drug interactions than some other cholinesterase inhibitors (such as donepezil or galantamine), because rivastigmine is primarily metabolised by cholinesterase-mediated hydrolysis at its site of action rather than by liver enzymes. Nevertheless, several clinically significant pharmacodynamic interactions exist.
Major Interactions
| Interacting Drug | Type of Interaction | Clinical Effect | Recommendation |
|---|---|---|---|
| Other cholinesterase inhibitors (donepezil, galantamine) | Pharmacodynamic – additive cholinergic effect | Excessive cholinergic stimulation, severe gastrointestinal effects, bradycardia | Do not combine. Use only one cholinesterase inhibitor at a time |
| Metoclopramide | Pharmacodynamic – opposing and synergistic effects | Muscle rigidity, joint stiffness, tremor, extrapyramidal symptoms | Avoid combination. Use alternative anti-emetics such as domperidone |
| Succinylcholine-type muscle relaxants | Pharmacodynamic – enhanced neuromuscular blockade | Prolonged neuromuscular block during anaesthesia, respiratory depression | Inform anaesthetist before surgery. Dose adjustment of muscle relaxant may be needed |
Moderate Interactions
| Interacting Drug | Type of Interaction | Clinical Effect | Recommendation |
|---|---|---|---|
| Beta-blockers (atenolol, metoprolol, bisoprolol) | Pharmacodynamic – additive bradycardic effect | Excessive slowing of heart rate (bradycardia), which may lead to dizziness, fainting, or loss of consciousness | Use with caution. Monitor heart rate regularly. Cardiologist consultation advisable |
| Anticholinergic medications (oxybutynin, tolterodine, antihistamines) | Pharmacodynamic – opposing effects | Reduced effectiveness of both Nimvastid and the anticholinergic drug | Avoid if possible. Review necessity of anticholinergic with prescriber |
| QT-prolonging drugs (amiodarone, certain antibiotics, antipsychotics) | Pharmacodynamic – additive cardiac effect | Increased risk of cardiac arrhythmias, including potentially fatal torsades de pointes | ECG monitoring recommended. Assess QTc interval before and during treatment |
| Cholinergic agonists (bethanechol, pilocarpine) | Pharmacodynamic – additive cholinergic effect | Excessive salivation, sweating, bradycardia, gastrointestinal distress | Combine with caution. Monitor for cholinergic excess |
If you are scheduled for surgery, it is essential to inform your surgeon and anaesthetist that you are taking Nimvastid. Rivastigmine may enhance the effects of succinylcholine-type muscle relaxants during general anaesthesia, potentially leading to prolonged neuromuscular blockade and respiratory complications. Your anaesthesia team may need to adjust the type or dose of muscle relaxant used.
What Is the Correct Dosage of Nimvastid?
Nimvastid treatment begins at 1.5 mg twice daily and is gradually increased in 1.5 mg steps at minimum 2-week intervals based on tolerability. The maximum dose is 6 mg twice daily (12 mg/day). Capsules should always be taken with food, swallowed whole, and never opened or crushed.
Nimvastid requires careful dose titration, starting at the lowest dose and gradually increasing it based on how well you tolerate the medication. Your doctor will guide you through this process and regularly evaluate whether the treatment is providing benefit. Your weight will also be monitored during treatment, as significant weight loss can occur.
Adults – Alzheimer's Dementia
Starting Dose
1.5 mg twice daily (3 mg total per day). Take one capsule in the morning and one in the evening, always with food.
Dose Titration
After a minimum of 2 weeks at each dose level, your doctor may increase the dose in 1.5 mg increments if you are tolerating the medication well. The titration schedule is typically: 1.5 mg → 3 mg → 4.5 mg → 6 mg twice daily.
Maximum Dose
6 mg twice daily (12 mg total per day). Not all patients will reach the maximum dose; the target is the highest dose that is well tolerated.
Adults – Parkinson's Disease Dementia
The dosage regimen for Parkinson's disease dementia is the same as for Alzheimer's dementia. Treatment starts at 1.5 mg twice daily with gradual titration up to a maximum of 6 mg twice daily. However, patients with Parkinson's disease may be more sensitive to cholinergic side effects, so dose increases may need to be slower and more cautious.
Elderly Patients
No specific dose adjustment is required based on age alone. However, elderly patients (particularly those over 85 years or weighing less than 50 kg) may be more susceptible to side effects. Dose titration should proceed cautiously, and the lowest effective dose should be used. Regular monitoring of weight, hydration status, and cognitive function is recommended.
Patients with Kidney or Liver Problems
In patients with mild to moderate kidney or liver impairment, no dose adjustment is typically needed. However, rivastigmine exposure may be increased in these populations, so careful dose titration and close monitoring for adverse effects is essential. In patients with severe hepatic impairment, Nimvastid should be used with particular caution as there is limited clinical experience in this group.
How to Take Nimvastid
- Take twice daily – once in the morning and once in the evening, with food
- Swallow capsules whole with a drink of water or another liquid
- Do not open, crush, or chew the capsules
- Always take with meals – food reduces the incidence of nausea and vomiting
- Tell your caregiver that you are taking Nimvastid so they can help ensure you take it correctly
Missed Dose
If you forget to take a dose of Nimvastid, simply wait until your next scheduled dosing time and take the usual dose. Do not take a double dose to make up for the missed one. If you have missed doses for more than 3 consecutive days, do not resume treatment without first consulting your doctor, as you may need to restart at the lowest dose to avoid severe side effects.
Overdose
If you accidentally take more Nimvastid than prescribed, contact your doctor or go to the nearest emergency department immediately. Symptoms of overdose may include severe nausea, vomiting, diarrhoea, elevated blood pressure, hallucinations, slow heart rate (bradycardia), and fainting. In severe cases, overdose can cause life-threatening cholinergic crisis characterised by extreme muscle weakness, respiratory failure, and cardiovascular collapse. The antidote for severe cholinergic toxicity is intravenous atropine.
What Are the Side Effects of Nimvastid?
The most common side effects of Nimvastid are gastrointestinal: nausea, vomiting, diarrhoea, and decreased appetite, affecting more than 1 in 10 patients. These are most likely during dose escalation and usually improve as the body adjusts. Serious but rare side effects include severe bradycardia, seizures, gastrointestinal bleeding, and pancreatitis.
Like all medicines, Nimvastid can cause side effects, although not everybody gets them. Side effects are most common when you first start treatment or when your dose is increased. In most cases, they gradually decrease as your body gets used to the medication. If any side effect becomes severe or persistent, contact your doctor, as dose adjustment may be necessary.
Very Common
- Dizziness
- Decreased appetite
- Nausea
- Vomiting
- Diarrhoea
Common
- Anxiety and agitation
- Excessive sweating
- Headache
- Heartburn (dyspepsia)
- Weight loss
- Abdominal pain
- Fatigue or weakness
- General feeling of being unwell (malaise)
- Tremor or confusion
- Nightmares
- Drowsiness (somnolence)
Uncommon
- Depression
- Difficulty sleeping (insomnia)
- Fainting (syncope) and accidental falls
- Elevated liver enzyme values
Rare
- Chest pain (angina pectoris)
- Skin rash and itching
- Seizures (convulsions)
- Stomach or intestinal ulcers
Very Rare
- High blood pressure (hypertension)
- Urinary tract infection
- Hallucinations (seeing things that are not there)
- Heart rhythm disturbances (tachycardia and bradycardia)
- Gastrointestinal bleeding (blood in vomit or stools)
- Pancreatitis (severe upper abdominal pain with nausea and vomiting)
- Worsening of Parkinson's symptoms or development of parkinsonism
Side Effects with Unknown Frequency
The following side effects have been reported but their frequency cannot be estimated from the available data:
- Severe vomiting that may lead to oesophageal tears (Mallory-Weiss syndrome)
- Dehydration resulting from prolonged vomiting or diarrhoea
- Liver function disorders – including jaundice (yellowing of skin or eyes), abnormally dark urine, unexplained nausea, fatigue, and appetite loss
- Aggression and restlessness
- Irregular heartbeat (cardiac arrhythmia)
- Pisa syndrome – a condition involving involuntary muscle contraction causing abnormal sideways bending of the body and head
Additional Side Effects in Patients with Parkinson's Disease Dementia
Patients with Parkinson's disease dementia may experience certain side effects more frequently. Very commonly (affecting more than 1 in 10 patients): tremor and accidental falls. Commonly (up to 1 in 10): anxiety, restlessness, slow and fast heart rate, insomnia, excessive salivation, dehydration, abnormally slow or uncontrolled movements, worsening of Parkinson's symptoms, hallucinations, depression, and high blood pressure.
Contact your doctor or seek emergency care immediately if you experience severe chest pain, signs of a severe allergic reaction (facial swelling, difficulty breathing, severe rash), severe vomiting with blood, black tarry stools, seizures, sudden confusion, or irregular heartbeat. These may indicate serious complications that require prompt medical evaluation.
How Should You Store Nimvastid?
Store Nimvastid capsules at room temperature, out of the sight and reach of children. No special storage conditions are required. Do not use after the expiry date printed on the packaging.
Keep Nimvastid in a safe place where children cannot see or reach it. Accidental ingestion of rivastigmine by a child could cause serious adverse effects and constitutes a medical emergency. Store the capsules in their original packaging to protect them from moisture and light.
There are no special temperature requirements for storing Nimvastid capsules. Standard room temperature conditions are suitable. Do not use the capsules after the expiry date stated on the blister or bottle and outer carton. The expiry date refers to the last day of the stated month.
Do not dispose of unused or expired Nimvastid capsules in household waste or down the drain. Return them to your pharmacy, where they will be disposed of safely in accordance with environmental protection regulations. This helps to prevent contamination of water supplies and protects the environment from pharmaceutical residues.
What Does Nimvastid Contain?
Each Nimvastid capsule contains rivastigmine hydrogen tartrate as the active ingredient, equivalent to 1.5 mg, 3 mg, 4.5 mg, or 6 mg of rivastigmine. Inactive ingredients include microcrystalline cellulose, hypromellose, colloidal anhydrous silica, and magnesium stearate, with the capsule shell made from gelatin and colourants.
Active Ingredient
The active substance is rivastigmine hydrogen tartrate. Each capsule contains the equivalent of 1.5 mg, 3 mg, 4.5 mg, or 6 mg of rivastigmine (free base). The hydrogen tartrate salt form is used to optimise the stability and bioavailability of the active substance.
Inactive Ingredients (Excipients)
Capsule contents: microcrystalline cellulose, hypromellose, colloidal anhydrous silica (silicon dioxide), and magnesium stearate.
Capsule shell for 1.5 mg: titanium dioxide (E171), yellow iron oxide (E172), and gelatin. The capsule has a yellow body and cap.
Capsule shell for 3 mg, 4.5 mg, and 6 mg: titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), and gelatin. The colour of the capsules varies by strength: 3 mg capsules are orange, 4.5 mg capsules are reddish-brown, and 6 mg capsules have a reddish-brown cap with an orange body.
Packaging
Nimvastid capsules are available in blister packs (PVC/PVDC/aluminium foil) containing 14 capsules (1.5 mg only), 28, 30, 56, 60, or 112 capsules, and in HDPE bottles containing 200 or 250 capsules. Not all pack sizes may be marketed in all countries.
Manufacturer
Nimvastid is manufactured by KRKA, d.d., Novo mesto, Slovenia, a major European pharmaceutical company with a reputation for producing high-quality generic medicines.
Frequently Asked Questions About Nimvastid
Nimvastid (rivastigmine) is used to treat mild to moderately severe Alzheimer's dementia and dementia associated with Parkinson's disease in adults. It belongs to a class of medications called cholinesterase inhibitors that work by increasing levels of the neurotransmitter acetylcholine in the brain, which helps to improve cognitive function, memory, attention, and the ability to carry out daily activities. Nimvastid does not cure dementia but can slow the progression of symptoms and help patients maintain independence for longer.
If you miss a single dose of Nimvastid, simply skip the missed dose and take your next dose at the regular scheduled time. Do not take a double dose to compensate. However, if you have missed doses for more than 3 consecutive days, it is important to contact your doctor before resuming the medication. Your doctor may advise you to restart treatment at the lowest dose (1.5 mg twice daily) and gradually re-titrate upward to avoid potentially severe gastrointestinal side effects that can occur when restarting at a higher dose after a break.
The most common side effects of Nimvastid (affecting more than 1 in 10 patients) are gastrointestinal in nature: dizziness, decreased appetite, nausea, vomiting, and diarrhoea. These side effects are typically most pronounced during the first few weeks of treatment and during dose increases. They usually diminish over time as the body adjusts to the medication. Taking Nimvastid with food can significantly reduce the severity of nausea and vomiting. If gastrointestinal side effects persist or become severe, your doctor may recommend slowing the dose titration or temporarily reducing the dose.
Nimvastid can be taken alongside many other medications, but there are important exceptions. It should never be combined with other cholinesterase inhibitors (such as donepezil or galantamine) or with metoclopramide. Caution is needed when taking Nimvastid with beta-blockers (risk of excessive heart rate slowing), anticholinergic medications (which oppose its effects), and drugs that can prolong the QT interval on an ECG. If you are planning to have surgery, inform your anaesthetist that you are taking Nimvastid, as it can intensify the effects of certain muscle relaxants used during anaesthesia.
Yes, Nimvastid and Exelon both contain exactly the same active ingredient – rivastigmine. Nimvastid is a generic version manufactured by the Slovenian pharmaceutical company KRKA, while Exelon is the original branded product by Novartis. Both medications have been demonstrated to be bioequivalent, meaning they deliver the same amount of active substance to the body at the same rate and produce identical therapeutic effects. Generic medicines undergo rigorous regulatory review by the EMA or national medicines agencies to ensure they meet the same standards of quality, safety, and efficacy as the originator product.
Nimvastid begins to have pharmacological effects within hours of taking a dose, but clinically meaningful improvement in cognitive symptoms typically takes several weeks to become apparent. Because the dose must be gradually increased over a period of at least 8 weeks to reach the therapeutic range (typically 3–6 mg twice daily), the full benefit of treatment is usually not seen until approximately 12–16 weeks after starting therapy. Your doctor will regularly assess the effectiveness of treatment. If no meaningful improvement is observed after 3–6 months at an adequate dose, your doctor will discuss whether to continue treatment.
References
- European Medicines Agency (EMA). Rivastigmine – Summary of Product Characteristics. European Medicines Agency. Available at: www.ema.europa.eu. Updated 2025.
- Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2015;(4):CD001191. doi:10.1002/14651858.CD001191.pub4
- Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351(24):2509–2518. doi:10.1056/NEJMoa041470
- World Health Organization. WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization; 2023.
- National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. NICE Guideline [NG97]. Updated 2023.
- American Academy of Neurology (AAN). Practice guideline update summary: Mild cognitive impairment. Neurology. 2018;90(3):126–135.
- Cummings J, Lee G, Nahed P, et al. Alzheimer's disease drug development pipeline: 2024. Alzheimers Dement (N Y). 2024;10(2):e12465.
- U.S. Food and Drug Administration (FDA). Exelon (rivastigmine) – Prescribing Information. FDA. Revised 2023.
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in neurology, geriatric medicine, and clinical pharmacology. Our team follows strict editorial standards based on the GRADE evidence framework, ensuring that all information is accurate, up-to-date, and based on the highest quality of available evidence.
Written by iMedic's medical content team with expertise in neurology and pharmacology. All content is based on peer-reviewed research and international clinical guidelines from the EMA, WHO, NICE, and AAN.
Independently reviewed by the iMedic Medical Review Board. Evidence level: 1A (systematic reviews and randomised controlled trials). Last reviewed: .
iMedic receives no pharmaceutical funding. All content is editorially independent. For questions about this article, contact us at our contact page.